Marfan Syndrome Clinical Trial
— LO-AT-MARFAN01Official title:
A Clinical Trial to Assess the Efficacy and Safety of Losartan Versus Atenolol in the Prevention of Progressive Dilation of the Aorta in Patients With Marfan Syndrome.
The purpose of this study is to evaluate the efficacy of Losartan versus Atenolol in the progression of aortic dilatation in patients with Marfan syndrome.
Status | Active, not recruiting |
Enrollment | 140 |
Est. completion date | February 2013 |
Est. primary completion date | February 2013 |
Accepts healthy volunteers | No |
Gender | Both |
Age group | 5 Years to 60 Years |
Eligibility |
Inclusion Criteria: 1. Subjects must conform to the diagnostic criteria Marfan syndrome according to the Ghent Criteria. 2. Outpatient subjects. 3. Male or female, aged between 5 and 60 years. 4. Women who are in a childbearing age are required a result of negative Gonadotropin pregnancy test to be included in the study. 5. Subjects must be able to take oral medication. 6. After having received information about the study, subjects must understand the nature of it and give written informed consent. 7. For Subjects under 18 years, the informed consent must be signed by their parents or guardians. 8. Subjects with a maximum diameter of the aorta, at length, <45 mm 9. Female subjects of childbearing potential must be willing to avoid pregnancy by using an adequate method of contraception for four weeks prior to, during and three months after the last dose study medication. For the purposes of this study, women of childbearing potential is defined as: All female subjects after puberty unless they are post-menopausal for at least two years, or are surgically sterile. Adequate contraception is defined as two barrier methods, or one barrier method with a spermicide, or an intrauterine device or use of the oral female contraceptive (or other hormonal methods). Exclusion Criteria: 1. Women who are pregnant, suspected to be pregnant or breast-feeding. 2. Ongoing participation in another clinical trial or who received the investigational drug in the month prior to the inclusion in the study. 3. Known or suspected failure to comply with the study protocol. 4. Previous surgery: cardiac or at any segment of the aorta. 5. Functional class III-IV. 6. Maximum diameter of the aorta exceeding 45 mm 7. More than moderate valvular involvement. 8. History or presence of respiratory failure, liver (ALT> 3 x ULN), renal (creatinine clearance <30 mL / min), gastrointestinal, hematological, endocrine, or any other situation that may affect the assessment of the study treatment, according to the investigator opinion. 9. History of aortic dissection. 10. History or presence of neurological disease (especially seizures, dementia ...). 11. History or presence of alcohol abuse and / or toxic substances 12. Uncontrolled depression. 13. Any need for another antihypertensive treatment (betablockers, diuretics, calcium channel blockers, ACE inhibitors, ARBs, etc.) 14. Hypersensitivity, intolerance or contraindication to any component of the study drug. 15. Patients with a history of drug abuse or toxic dependence. |
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention
Country | Name | City | State |
---|---|---|---|
Spain | Hospital Vall d'Hebron | Barcelona | |
Spain | Hospital 12 de Octubre | Madrid |
Lead Sponsor | Collaborator |
---|---|
Forteza, Albert, M.D. | Ministry of Health, Spain |
Spain,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Progression of aortic dilation in patients with Marfan syndrome. | Evaluate the eficacy of Losartan versus Atenolol in the progression of aortic dilation in patients with Marfan syndrome. | Until February 2013 | No |
Status | Clinical Trial | Phase | |
---|---|---|---|
Terminated |
NCT00763893 -
Study of the Efficacy of Losartan on Aortic Dilatation in Patients With Marfan Syndrome
|
Phase 3 | |
Recruiting |
NCT05809323 -
Marfan Syndrome Moderate Exercise Trial II
|
N/A | |
Completed |
NCT04776668 -
Living With Marfan Syndrome and Your Aorta
|
||
Recruiting |
NCT01949233 -
The Oxford Marfan Trial
|
Phase 2 | |
Completed |
NCT00723801 -
Effects of Losartan Versus Atenolol on Aortic and Cardiac Muscle Stiffness in Adults With Marfan Syndrome
|
Phase 3 | |
Completed |
NCT04641325 -
Marfan Syndrome Moderate Exercise Pilot
|
N/A | |
Recruiting |
NCT06257004 -
Genome-wide Epistasis for Cardiovascular Severity in Marfan Study
|
||
Completed |
NCT01322165 -
National Registry of Genetically Triggered Thoracic Aortic Aneurysms and Cardiovascular Conditions
|
N/A | |
Recruiting |
NCT05700175 -
Transcriptomic Study of Adult Population With Marfan Syndrome
|
||
Completed |
NCT00782327 -
Randomized, Double-blind Study for the Evaluation of the Effect of Losartan Versus Placebo on Aortic Root Dilatation in Patients With Marfan Syndrome Under Treatment With Beta-blockers
|
Phase 3 | |
Not yet recruiting |
NCT05838235 -
Adapted Physical Activity Program (APA) for Effort Rehabilitation of Children and Teenagers With Marfan Syndrome
|
N/A | |
Recruiting |
NCT02148900 -
Development of a Blood Test for Marfan Syndrome
|
N/A | |
Active, not recruiting |
NCT05980104 -
Single-Session "Empowered Relief" Class for Marfan Syndrome and Related Conditions
|
N/A | |
Recruiting |
NCT02050113 -
Complex Aortic Aneurysm Repair Using Physician Modified Endografts and Custom Made Devices
|
N/A | |
Completed |
NCT00001641 -
Study of Heritable Connective Tissue Disorders
|
N/A | |
Completed |
NCT01715207 -
Comparison Study of the Effect of Aliskiren Versus Negative Controls on Aortic Stiffness in Patients With Marfan Syndrome Under Treatment With Atenolol
|
Phase 3 | |
Completed |
NCT05516043 -
Safety and Performance of POLYTHESE® Vascular Prosthesis
|
||
Recruiting |
NCT04776681 -
Living With Marfans and Your Aorta: Surgical Outcomes Study
|
||
Completed |
NCT03236571 -
Cardiorespiratory and Muscular Rehabilitation of Children and Young Adults With Marfan Syndrome.
|
N/A | |
Recruiting |
NCT00683124 -
Nebivolol Versus Losartan Versus Nebivolol+Losartan Against Aortic Root Dilation in Genotyped Marfan Patients
|
Phase 3 |